Physician profile
Rocco Grella
NPI 1689780819
$6,170.45
in general payments reported to CMS, 2019-2025
14 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.79 · 2020: $149 · 2021: $57.35 · 2022: $58.81 · 2023: $4,215 · 2024: $1,160 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,801 · Food and Beverage: $935 · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,801.48 |
| Food and Beverage | $934.66 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,124.57 | 2023-2024 | Micra, Azure Xt Dr Mri Surescan, Advisa Dr Mri Surescan |
| Shockwave Medical, INC | $278.33 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Stryker Corporation | $165.80 | 2025 | Flowtriever |
| Abbott Laboratories | $110.14 | 2020-2023 | Perclose Prostyle |
| Novartis Pharmaceuticals Corporation | $103.84 | 2021-2025 | |
| Pfizer INC. | $102.72 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $71.99 | 2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.59 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $40.33 | 2022-2023 | Farxiga |
| Amgen INC. | $32.30 | 2019-2025 | Repatha |
| Terumo Medical Corporation | $21.05 | 2025 | Glidesheath Slender, Glidewire, Angio-Seal |
| Chiesi USA, INC. | $18.18 | 2019 | |
| Gilead Sciences, INC. | $16.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocco Grella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.